Clinical Trial

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2023 (before its estimated August 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-25; most recent amendment 2023-11-21.
Trial Details
NCT Number NCT05069857
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
Enrollment 46 participants
Start Date 2021-09-01
Primary Completion 2024-08-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-22